N@N

Benjamin Chaiken Reiterated (BPMC) at Hold and Held Target at $114 on, Feb 28th, 2023

Benjamin Chaiken of JMP Securities, Reiterated "Blueprint Medicines Corporation" (BPMC) at Hold and Held Target at $114 on, Feb 28th, 2023.

Benjamin has made no other calls on BPMC in the last 4 months.

There are 10 other peers that have a rating on BPMC. Out of the 10 peers that are also analyzing BPMC, 5 agree with Benjamin's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $38 on, Friday, February 24th, 2023
• Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $50 on, Friday, January 27th, 2023
• Peter Lawson of "Barclays" Maintained at Hold with Decreased Target to $44 on, Monday, January 23rd, 2023
• Derek Archila of "Wells Fargo" Upgraded from Sell to Hold and Held Target at $41 on, Tuesday, January 3rd, 2023
• Matthew Biegler of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, November 2nd, 2022

These are the ratings of the 5 analyists that currently disagree with Benjamin

---

• Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $85 on, Friday, February 17th, 2023
• Reni Benjamin of "JMP Securities" Reiterated at Buy and Held Target at $114 on, Monday, February 6th, 2023
• Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $108 on, Thursday, November 3rd, 2022
• Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $106 on, Wednesday, November 2nd, 2022
• Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Decreased Target to $85 on, Wednesday, November 2nd, 2022

Contributing Sources

---